Génomique fonctionnelle et innovations thérapeutiques dans les leucémies aiguës lymphoblastiques T.

T-acute lymphoblastic leukaemia (T-ALL) accounts for 25% of adult ALL and 15% of childhood ALL. Their prognosis, long considered more unfavourable than that of B-ALL, has improved significantly in recent years. However, there remains a major challenge in this disease. Nearly 20% of patients will suffer a relapse, which is still associated with an extremely poor prognosis (less than 20% survival at five years). While advances in molecular biology in recent years have led to the identification of a large number of potentially targetable alterations involved in T oncogenesis, the therapeutic arsenal for relapsed or refractory disease remains limited to date, and only a few innovative therapies have been developed. Unlike B-ALL, T-ALL has not benefited from the immunotherapy revolution, with the development of bispecific antibodies and CAR T-cells for B haemopathies. There is therefore an urgent need to identify new therapeutic targets, which should lead in the short term to the development of new therapies that are lacking in this disease. This review presents recent advances in the oncogenesis of T-ALL and the potential therapeutic opportunities associated with them. [ABSTRACT FROM AUTHOR]